Early trial pairs arthritis and cancer drugs to fight tough lung tumors
NCT ID NCT05704634
Summary
This early-stage study is testing whether combining an existing arthritis drug (sarilumab) with an existing cancer immunotherapy (cemiplimab) can help control advanced non-small cell lung cancer. It is enrolling 56 adults whose cancer has specific genetic changes (EGFR or LKB1 mutations) and has progressed after standard treatments. The main goals are to see if the combination is safe and shows early signs of slowing the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.